TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Leishmaniasis
New research on leishmaniasis from United Nations Children's Fund summarized
March 3rd, 2009
"To estimate drug costs of treating visceral leishmaniasis (VL) based on data on the VL population structure from the high-burden, antimony-resistant area of Northern Bihar, India. Paromomycin is the cheapest option ($7450 to treat 1000 patients)," scientists in Geneva, Switzerland report. "Treating 1000 patients with oral miltefosine would cost $119 250 at the current private market price or $64 383-$75 129 at preferential public sector price depending on the size of the order. With AmBisome((R)) it would be $163 600 or $229 500 depending on the dose (10 or 15 mg/kg total). These costs are without considering other direct costs (daily intramuscular injections for 3...
Source: TB & Outbreaks Week (2009-03-03)
|
